Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
D000218:Adamantane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D004338:Drug Combinations; D005060:Europe; D006801:Humans; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D004338:Drug Combinations; D009570:Nitriles; D011759:Pyrrolidines; D008687:Metformin; D000218:Adamantane